Our research is aimed at elucidating the mechanism of adult T-cell leukemia/lymphoma development at the molecular and individual levels and developing new preventive and therapeutic methods.
The mission of our research group is to develop new therapeutics against certain refractory viral infections such as HIV and HBV. We also aim to establish novel strategies to combat with emerging diseases including COVID-19.!--
Div. of Antiviral Chemotherapy
We are studying the pathogenesis and therapy of retrovirus (HIV-1 and HTLV-1) infections,
including the identification and preclinical development of novel anti-AIDS agents, anticancer drugs against adult T-cell leukemia (ATL), and nanotechnology-based antiviral vaccine adjuvants.
In addition, investigations on anti-HBV and HCV agents are also in progress.